Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
World J Hepatol ; 5(2): 74-81, 2013 Feb 27.
Artigo em Inglês | MEDLINE | ID: mdl-23646232

RESUMO

AIM: To study serum levels of leptin and adiponectin in patients with chronic hepatitis C virus infection genotype-4 (HCV-4) related steatosis and fibrosis. METHODS: We prospectively studied 45 untreated men with chronic HCV-4, with proven steatosis (group I, 30 patients), and fibrosis (group II, 15 patients), on liver biopsy. In addition, 15 healthy men (group III), matched for age, and body mass index were included. However, we excluded another five patients with steatohepatitis, and six patients with cirrhosis. We measured total serum leptin and adiponectin levels, as potential predictors for liver steatosis and fibrosis. Also, a correlation between these adipokines and various clinical and laboratory data were evaluated. All subjects were selected from Tropical and Internal medicine departments, Menoufiya University Hospital, Menoufiya, Egypt, during the period from February 2010 to August 2011. RESULTS: In group I, severity of hepatic steatosis was mild, moderate, and severe, in 19 patients (63.5%), 8 patients (26.5%), and 3 patients (10%), respectively. In contrast, in group II, hepatic fibrosis was found to be in stage 1, 2, and 3, in 6 patients (40%), in 6 patients (40%), and in 3 patients (20%), respectively. On comparing group I with group II, there was a significant decrease in serum adiponectin levels (131.4 ± 7.91 pg/mL vs 436 ± 9.75 pg/mL, P < 0.001), while there was no significant difference between both groups regarding serum leptin levels (34.69 ± 7.69 ng/mL vs 35.17 ± 1.06 ng/mL, P > 0.05). However, in the same group, when compared with group III, there was a significant increase in serum leptin levels (34.69 ± 7.69 ng/mL vs 10.69 ± 0.84 ng/mL, P < 0.001), while there was a significant decrease in serum adiponectin levels (131.4 ± 7.91 pg/mL vs 342.4 ± 44.48 pg/mL, P < 0.001). In contrast, in group II, when compared with group III, there was a significant increase in serum leptin and adiponectin levels (35.17 ± 1.06 ng/mL vs 10.69 ± 0.84 ng/mL, P < 0.001, and 436 ± 9.75 pg /mL vs 342.4 ± 44.48 pg/mL, P < 0.05, respectively), while there was no significant difference between both groups regarding serum creatinine (0.83 ± 0.34 vs 0.89 ± 0.24, P > 0.05). On the other hand, serum leptin was not correlated with serum adiponectin in group I and in group II (r = 0.09, P > 0.05, and r = -0.1, P > 0.05, respectively). However, serum adiponectin was significantly negatively correlated with serum aspartate transaminase in group I, but no correlation detected in group II (r =-0.39, P > 0.05, and r = -0.03, P > 0.05). CONCLUSION: In male patients with chronic HCV-4, serum adiponectin levels are elevated in hepatic fibrosis, but decreased in steatosis. Therefore, in contrast to leptin, adiponectin may be used as a non-invasive marker.

2.
Postgrad Med J ; 87(1029): 463-7, 2011 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-21447495

RESUMO

AIM: Human resistin is an adipokine, with a possible link to coronary heart disease, and the relationship between serum resistin, insulin resistance, and type 2 diabetes mellitus (T2DM) remains controversial. Therefore, this study assessed serum resistin in patients with acute ST segment elevation myocardial infarction (STEMI), with and without T2DM. METHODS: Between June 2009 and July 2010, 55 subjects were recruited into three groups: 20 non-diabetic patients with acute STEMI (group 1), 20 diabetic patients with acute STEMI (group 2), and 15 healthy controls (group 3). Concentrations of serum lipids, fasting blood glucose (FBG), insulin, troponin I, creatine kinase (CK), lactate dehydrogenase (LDH), and resistin, were estimated. RESULTS: Concentrations of serum total cholesterol, low density lipoprotein cholesterol, FBG, troponin I, CK, LDH, and resistin were significantly higher in group 2 subjects, than in those in groups 1 and 3 (p<0.05). In group 2, serum resistin was positively correlated with serum troponin I and triglycerides (r=0.59, p<0.05, and r=0.47, p<0.05, respectively), but was negatively correlated with high density lipoprotein cholesterol (r=-0.46, p<0.05). However, in this group, serum resistin was not correlated with age, gender, body mass index (BMI), total cholesterol, FBG, insulin, CK, LDH, and the calculated homeostasis model for insulin resistance (HOMA-IR) (p>0.05). Regarding group 1, serum resistin was not correlated to any of these studied parameters (p>0.05). CONCLUSIONS: Serum resistin concentrations are elevated in patients with acute STEMI. This increase is more prominent in patients with T2DM than in those without. However, serum resistin is not correlated with age, gender, BMI, and insulin resistance. These data suggest that serum resistin concentration might be used as a diagnostic biomarker for acute STEMI.


Assuntos
Diabetes Mellitus Tipo 2/sangue , Infarto do Miocárdio/sangue , Resistina/sangue , Idoso , Biomarcadores/sangue , Índice de Massa Corporal , Estudos de Casos e Controles , Colesterol/sangue , LDL-Colesterol/sangue , Creatina Quinase/sangue , Feminino , Humanos , L-Lactato Desidrogenase/sangue , Masculino , Pessoa de Meia-Idade , Troponina I/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...